These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37733192)

  • 21. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis.
    Mallawaarachchi G; Rog DJ; Das J
    Mult Scler Relat Disord; 2024 Jan; 81():105153. PubMed ID: 38043364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial/Ethnic Differences in Psychiatric and Medical Diagnoses Among Autistic Adults.
    Ames JL; Morgan EH; Onaiwu MG; Qian Y; Massolo ML; Croen LA
    Autism Adulthood; 2022 Dec; 4(4):290-305. PubMed ID: 36601333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.
    Amezcua L; Smith JB; Gonzales EG; Haraszti S; Langer-Gould A
    Neurology; 2020 Apr; 94(14):e1548-e1556. PubMed ID: 32152131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
    Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
    Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.
    Manzano GS; Holroyd KB; Kaplan T; Bhattacharyya S; Chitnis T; Hotan G; Zurawski J; Galetta KM; Mateen FJ
    Mult Scler Relat Disord; 2022 Jul; 63():103861. PubMed ID: 35576727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region.
    Hittle M; Culpepper WJ; Langer-Gould A; Marrie RA; Cutter GR; Kaye WE; Wagner L; Topol B; LaRocca NG; Nelson LM; Wallin MT
    JAMA Neurol; 2023 Jul; 80(7):693-701. PubMed ID: 37184850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    Spierer R; Lavi I; Bloch S; Mazar M; Golan D
    J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    Habek M; Jakob Brecl G; Bašić Kes V; Rogić D; Barun B; Gabelić T; Emeršič A; Horvat Ledinek A; Grbić N; Lapić I; Šegulja D; Đurić K; Adamec I; Krbot Skorić M
    J Neuroimmunol; 2021 Oct; 359():577696. PubMed ID: 34418815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland.
    Podlecka-Piętowska A; Sierdziński J; Nojszewska M; Stawicki J; Bartosik-Psujek H; Lech B; Popiel M; Perenc A; Kułakowska A; Czarnowska A; Kulikowska J; Kapica-Topczewska K; Jamróz-Wiśniewska A; Rejdak K; Zaborski J; Kubicka-Bączyk K; Niedziela N; Wierzbicki K; Adamczyk-Sowa M; Zwiernik J; Zwiernik B; Milewska-Jędrzejczak M; Głąbiński A; Jasińska E; Puz P; Krzystanek E; Stęposz A; Karuga A; Lasek-Bal A; Siuda J; Kściuk B; Walawska-Hrycek A; Patalong-Ogiewa M; Kaczmarczyk A; Siutka K; Brola W; Zakrzewska-Pniewska B
    Neurol Neurochir Pol; 2024; 58(1):112-119. PubMed ID: 38251955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations.
    Stahmann A; Craig E; Ellenberger D; Fneish F; Frahm N; Marrie RA; Middleton R; Nicholas R; Rodgers J; Warnke C; Salter A
    Ther Adv Neurol Disord; 2024; 17():17562864241233044. PubMed ID: 38495364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State-Level Cardiovascular Mortality Rates Among Hispanic, Non-Hispanic Black, and Non-Hispanic White Populations, 1990 to 2019.
    Johnson CO; DeCleene NK; Blacker BF; Cunningham MW; Aravkin A; Dieleman JL; Gakidou E; Naghavi M; Ogunniyi MO; Zheng P; Roth GA
    JAMA Cardiol; 2023 May; 8(5):429-442. PubMed ID: 36920376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of multiple sclerosis and treatment utilization in a large, highly diverse population.
    Carlson AM; Sollero CV; Nair KV; Sillau S; Wu Q; Gyang T; Li Z; Armstrong MJ
    Mult Scler Relat Disord; 2022 May; 61():103784. PubMed ID: 35405561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Teni FS; Machado A; Fink K; Gyllensten H; Hillert J; Friberg E
    Mult Scler; 2024 Mar; 30(3):419-431. PubMed ID: 38243631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of Influenza-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death by Race and Ethnicity in the United States From 2009 to 2019.
    O'Halloran AC; Holstein R; Cummings C; Daily Kirley P; Alden NB; Yousey-Hindes K; Anderson EJ; Ryan P; Kim S; Lynfield R; McMullen C; Bennett NM; Spina N; Billing LM; Sutton M; Schaffner W; Talbot HK; Price A; Fry AM; Reed C; Garg S
    JAMA Netw Open; 2021 Aug; 4(8):e2121880. PubMed ID: 34427679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study.
    Das J; Mallawaarachchi G; Grimshaw J; Jackson T; Talbot P; Sharaf N; Kalatha T; Lord L; Pace A; Mihalova T; Heal C; Rog D
    J Neurol Neurosurg Psychiatry; 2024 Jun; ():. PubMed ID: 38839276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States.
    Kern DM; Cepeda MS
    BMC Neurol; 2020 Aug; 20(1):296. PubMed ID: 32781983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.